

21 October 2025

Botanix to present at Canaccord Drug and Device Conference in Noosa

Philadelphia and Phoenix US, 21 October 2025: Clinical dermatology company Botanix Pharmaceuticals Limited (ABN 70 009 109 755) (ASX:BOT, "Botanix" or "the Company") is pleased to announce that their Chief Executive Officer, Dr Howie McKibbon, will be a featured presenter today at the Canaccord Drug and Device Healthcare Conference in Noosa. Following the presentation, Dr McKibbon and US Chief Financial Officer Chris Lesovitz will participate in roundtable discussions with institutional investors attending the meeting. Canaccord Genuity will host a Botanix investor roadshow for the balance of the week.

The Company will present a subset of the attached presentation.

This ASX announcement is authorised for release by the Board.

About Botanix Pharmaceuticals

Botanix Pharmaceuticals Limited (ASX: BOT) is a dermatology company based in Philadelphia and Phoenix (US), which has received FDA approval for its lead product *Sofdra*® for the treatment of primary axillary hyperhidrosis. *Sofdra* is the first and only new chemical entity approved by FDA to treat primary axillary hyperhidrosis and presents a novel safe and effective solution for patients who have lacked treatment options for this socially challenging medical condition.

To learn more, please visit: http://www.botanixpharma.com/

For more information, please contact:

General enquiries	Investor enquiries	Media enquiries
Corporate Communications	Hannah Howlett	Haley Chartres
Botanix Pharmaceuticals	WE Communications	H^CK
P: +61 8 6555 2945	P: +61 450 648 064	P: +61 423 139 163
investors@botanixpharma.com	hhowlett@we-worldwide.com	haley@hck.digital

Cautionary Note on Forward-Looking Statements

Forward-looking statements can generally be identified by the use of forward-looking words such as, "expect", "anticipate", "likely", "intend", "should", "could", "may", "predict", "plan", "propose", "will", "believe", "forecast", "estimate", "target" "outlook", "guidance" and other similar expressions and include, but are not limited to, plans and prospects for the Company, the Company's strategy, future operations, the expected timing and/or results of regulatory approvals and prospects of commercialising product candidates or research collaborations with its partners, including in Japan,



the outcome and effects of *Sofdra* and the market for *Sofdra*. Indications of, and guidance or outlook on, future earnings or financial position or performance are also forward-looking statements. The forward-looking statements contained in this announcement are not indications, guarantees or predictions of future performance and involve known and unknown risks and uncertainties and other factors, many of which are beyond the control of Botanix, and may involve significant elements of subjective judgement and assumptions as to future events which may or may not be correct. Investors should consider the forward-looking statements contained in this announcement in light of those disclosures and not place undue reliance on such statements. Except as required by law or regulation, Botanix undertakes no obligation to update forward-looking statements.



Sofdra Important Safety Information & Indication

Indication

Sofdra (sofpironium) topical gel, 12.45% is a prescription anticholinergic medicine used on the skin (topical) to treat excessive underarm sweating (primary axillary hyperhidrosis) in adults and children 9 years of age and older.

IMPORTANT SAFETY INFORMATION

Sofdra is for use on the skin in the underarm area only. Wash your hands right away after you apply Sofdra. Do not touch your underarms after applying Sofdra. Sofdra is flammable. Avoid heat and flame while applying Sofdra.

Who should not use Sofdra?

Do not use *Sofdra* if you have certain medical conditions that can be made worse by taking an anticholinergic medicine such as glaucoma, severe ulcerative colitis (UC) or certain other serious bowel problems associated with severe UC, myasthenia gravis, and Sjogren's syndrome.

What should I tell my healthcare provider before using Sofdra?

- Tell your healthcare provider about all of your medical conditions, including bladder or kidney problems, problems passing urine, if you are pregnant or breastfeeding, or plan to become pregnant or breastfeed. It is not known if Sofdra will harm your unborn baby or pass into your breast milk.
- Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, especially any anticholinergic medicines.

What are possible side effects of Sofdra?

Serious side effects may include:

- **Blurred vision.** Stop using *Sofdra*, call your healthcare provider right away, and do not drive or operate machinery or do hazardous work until your vision is clear.
- **New or worsened urinary retention.** Stop using *Sofdra* and call your healthcare provider right away if you experience difficulty urinating, urinating frequently, urination in a weak stream or drips, full bladder or difficulty emptying your bladder.

The most common side effects of *Sofdra* include dry mouth; blurred vision; pain, redness, swelling, itching, and irritation in the underarm area; dilation of the pupils of your eyes (mydriasis); and problems with urination. These are not all of the possible side effects of *Sofdra*. Call your doctor for medical advice about side effects.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088. You may also report side effects to Botanix at 1-866-763-6337.

Keep Sofdra and all medicines out of the reach of children.





Q1 FY26 Investor Update

20 October 2025

Important Notices & Disclaimer

1. Summary information

The following notice and disclaimer applies to this investor presentation ("Presentation") and you are therefore advised to read this carefully before reading or making any other use of this Presentation or any information contained in this Presentation. By accepting this Presentation, you represent and warrant that you are entitled to receive this Presentation in accordance with the restrictions, and agree to be bound by the limitations, contained within it. This Presentation is dated 20 October 2025 and has been prepared by Botanix Pharmaceuticals Limited (ABN 70 009 109 755) ("Botanix" or "the Company"). The information contained in this Presentation is of a general nature and does not purport to be complete nor does it contain all the information which a prospective investor may require in evaluating a possible investment in the Company or that would be required in a prospectus or product disclosure statement prepared in accordance with the requirements of the Corporations Act 2001 (Cth). The information contained in this Presentation is a summary only and should be read in conjunction with the Company's other periodic and continuous disclosure announcements lodged with the Australian Securities Exchange ("ASX"), which are available at www.asx.com.au.

2. Not an offe

Each recipient of this Presentation should make its own enquiries and investigations regarding all information in this Presentation including but not limited to the assumptions, uncertainties and contingencies which may affect future operations of the Company and the impact that different future outcomes might have on the Company and form their own views as to what information is relevant to such decisions and made their own investigations in relation to any additional information. This Presentation does not constitute investment or financial product advice (nor tax, accounting or legal advice) or any recommendation to acquire shares and does not and will not form any part of any contract for the acquisition of shares. Information in this Presentation is not intended to be relied upon as advice to investors or potential investors and has been prepared without taking account of any person's individual investment objectives, financial situation or particular needs. Before making an investment decision, prospective investors should consider the appropriateness of the information having regard to their own investment objectives, financial situation and needs and seek legal, accounting and taxation advice appropriate to their jurisdiction. The Company is not licensed to provide financial product advice in respect of its securities.

3. Not investment advice

This Presentation does not constitute or contain an offer, invitation, solicitation or recommendation to subscribe for, acquire or sale of any securities in Botanix, or any other financial products or securities, in any place or jurisdiction. This Presentation is not a prospectus, product disclosure statement or other offering document under Australian law or any other law and will not be lodged with the Australian Securities and Investments Commission. Persons who come into possession of this Presentation should observe any such restrictions as any non-compliance could contravene applicable securities laws.

4. Industry data

Certain market and industry data used in connection with or referenced in this Presentation has been obtained from public filings, research, surveys or studies made or conducted by third parties, including as published in industry-specific or general publications. Neither Botanix nor its advisers, or their respective representatives, have independently verified any such market or industry data.

5. Financial data

All dollar values are in Australian dollars (\$ or A\$) unless otherwise stated. Amounts, totals and change percentages are calculated on whole numbers and not the rounded amounts presented.

6. Forward-looking statements and forecasts

This Presentation contains certain "forward-looking statements" and comments about future matters. Forward-looking statements can generally be identified by the use of forward-looking words such as, "expect", "anticipate", "fintend", "should", "could", "may", "predict", "plan", "propose", "will", "believe", "forecast", "estimate", "target" "outlook", "guidance" and other similar expressions and include, but are not limited to, plans and prospects for the Company, the Company's strategy, future operations, the expected timing and/or results of regulatory approvals and prospects of commercialising product candidates or research collaborations with its partners, including in Japan, the outcome and effects of *Sofdra*® and the market for *Sofdra*®. Indications of, and guidance or outlook on, future earnings or financial position or performance are also forward-looking statements. You are cautioned not to place undue reliance on forward-looking statements, opinions and estimates in this Presentation speak only as of the date hereof, are preliminary views and are based on assumptions and contingencies subject to change without notice, as are statements about market and industry trends, projections, guidance and estimates. Forward-looking statements are provided as a general guide only. The forward-looking repetitions of future performance and involve known and unknown risks and uncertainties and other factors, many of which are beyond the control of Botanix, and may involve significant elements of subjective judgement and assumptions as to future events which may or may not be correct. Any such forward-looking statements are also based on assumptions and contingencies which are subject to change and which may ultimately prove to be materially incorrect, as are statements about market and industry trends, which are based on interpretations of current market conditions. Investors should consider the forward-looking statements contained in this Presentation in light of those disclosures and not place undue reliance on s

7. Disclaimer

The Company and its related bodies corporate and each of their respective directors, agents, officers, employees and advisers expressly disclaim, to the maximum extent permitted by law, all liabilities (however caused, including negligence) in respect of, make no representations regarding, and take no responsibility for, any part of this presentation and make no representation or warranty as to the currency, accuracy, reliability or completeness of any information, statements, opinions, conclusions or representations contained in this presentation. In particular, this Presentation does not constitute, and shall not be relied upon as, a promise, representation, warranty or guarantee as to the past, present or future performance of the Company.

This Presentation is authorised for release by the Board.




Operations: Suite 1340, 100 Front Street Conshohocken PA 19428 Corporate Office: Suite 3, 41-47 Colin St West Perth WA 6005 Authorised for release by the Board of Directors of Botanix

Suite 202, 2390 E Camelback Road Phoenix AZ 85016

Q1 FY2026 Quarterly Update Overview



Corporate Overview



Launching *Sofdra*®, the first new chemical entity to treat primary axillary hyperhidrosis (PAH)



Q1 Commercial Highlights

- Continued TRx growth of Sofdra
- Quarter over quarter increase in Net Sales and Gross to Net yield
- Highly productive sales team



Q1 Financial Highlights

- Strong capital position to support growth plans and profitability
- Reduced net operating cash outflow



Corporate overview: Fast-growing dermatology pharmaceutical company with successful launch of lead product for hyperhidrosis

Dermatology Focused

Sofdra® is the first and only new chemical entity (sofpironium) to treat primary axillary hyperhidrosis

Innovative Platform

Fulfillment platform increases patient compliance and improves gross-to-net (GTN)

Strong Capital Position

Cash of A\$49.2m, and additional A\$15.2 million of undrawn debt capacity¹ **Positioned for Growth**

Sales force expansion to 50 sales professionals is complete



Botanix is led by an experienced group of dermatology executives



VINCE IPPOLITO
Executive Chairman







HOWIE MCKIBBON
Chief Executive Officer

ANACOR"





CAREY HERBERTChief Legal & Compliance Officer





CHRIS LESOVITZ
Chief Financial Officer, U.S.





>30
successful
dermatology
product
launches

developed, secured approval for, and commercialized





LEISHA MARTINVP, Quality, Regulatory & PV











PAUL SEABACK
Chief Technical Officer









MARTINA CARTWRIGHT

VP, Medical Affairs











Primary hyperhidrosis affects twice as many patients as psoriasis and is the third largest patient category in dermatology





Sofdra® is the first and only new chemical entity for primary axillary hyperhidrosis, providing a safe and effective treatment option

Sofdra binds selectively to M3 receptors in the sweat gland, blocks acetylcholine to inhibit sweat, and is rapidly metabolised¹



FDA-Approved Indication²

The treatment of primary axillary hyperhidrosis (PAH) in adults and pediatric patients 9 years of age and older

Efficacy²

High statistical significance across co-primary endpoints: Patient Reported (HDSM-Ax-7) and Objective (GSP)

Safety and Tolerability²

Well-tolerated with adverse events that were mostly mild or moderate and transient; No serious TEAEs were reported


Proprietary Drug Delivery System

Applicator helps limit unwanted drug contact to hands during application and ensures consistent dosing





The Botanix Fulfilment Platform offers an innovative approach with frictionless access to *Sofdra®* for dermatologists and patients





Q1 FY2026: Strong Sofdra® TRx Growth

Quarterly Commercial Highlights:

20,418 TRx

• Total prescriptions shipped grew 50% vs Q4, driven by our fulfilment platform and productive sales team

\$7.1m
Net Sales


Net sales increased 65% quarter over quarter

23%
Gross to Net Yield

Gross to net yield continues to improve





Sofdra® TRx shipments grew to 20,418 in Q1 FY26





Net revenue is accelerating in step with prescription growth while gross to net yield continues to improve







Q1 FY2026: Strong Financial Fundamentals

Quarterly Financial Highlights:

\$(13.1M)
Operating Cash
Outflow

 Operating cash outflows decreased by \$15.3m to \$13.1m, driven by increased receipts from product sales alongside decreased operating and product manufacturing costs

~\$29M Inventory Balance

 Inventory balance sufficient to support sales force expansion in Q2 FY26

\$64.4M

Available Funding


- Cash and cash equivalents of \$49.2 million
- Undrawn debt of \$15.2 million¹
- Stable cash position provides runway to support Sofdra® growth



Significant overall reductions due to disciplined financial approach

Cash flows from operating activities	31-Dec-24	31-Mar-25	30-Jun-25	30-Sep-25		
Receipt from Royalties	423	218	195	504		
Receipts from product sales, net of fees		326	3,836	8,271	0/ Change 04 EV2E to 04 EV26	
Payments for gross to net deductions from product sales				(2,666)	<u>% Change Q4 FY25 to Q1 FY26</u>	
Payments for:						
a) Product manufacturing	(11,548)	(3,434)	(11,156)	(2,171)	Product manufacturing costs dropped 81%	
b) Operating costs	(6,927)	(12,702)	(14,358)	(10,241)		
c) Staff Costs	(2,426)	(2,244)	(4,513)	(3,471)	One wating seets fall 200/	
d) G&A	(2,169)	(2,403)	(2,401)	(1,873)	Operating costs fell 29%	
e) Royalty Payments				(495)		
Interest received	563	327	363	402	Staff costs declined 23%	
Interest paid			(264)	(531)		
R&D Refund	1,500				C9 A decreed 220/	
Net GST	1	(51)	(112)		G&A decreased 22%	
Other non-recurring payment				(844)		
Net cash from / (used in) operating activities	\$(20,583)	\$(19,963)	\$(28,410)	\$(13,115)	■ Net cash outflow decreased from \$28.4m	
Cash flows from financing activities					to \$13.1m	
Proceeds from issues of equity securities			40,000		to \$13.1III	
Proceeds from exercise of options				21		
Transaction costs related to issues of equity securities			(2,400)			
Proceeds from borrowings			30,746			
Transaction costs related to loans and borrowings			(2,615)	(2,331)		
Dividends paid			(20)			
Other (Payment for right-of-use asset)	(116)	(132)	(137)	(108)		
Net cash from / (used in) financing activities	\$(116)	\$(132)	\$65,574	\$(2,418)		
Net increase / (decrease) in cash and cash equivalents for the period						
Cash and cash equivalents at beginning of period	\$68,672	\$48,358	\$28,080	\$64,888		
Net cash from / (used in) operating activities	(20,583)	(19,963)	(28,410)	(13,115)		
Net cash from / (used in) investing activities						
Net cash from / (used in) financing activities	(116)	(132)	65,574	(2,418)		
Effect of movement in exchange rate on cash	385	(183)	(356)	(109)		
Cash and cash equivalents at end of period	\$48,358	\$28,080	\$64,888	\$49,246		

Our sales force has been highly productive, generating more TRx per rep than other recent dermatology launches





Expanded high-productivity salesforce to meet Sofdra® demand





27 Active Sales Professionals



20 Oct 2025

50 Active Sales Professionals







Interest in *Sofdra*® is high amongst dermatologists with presentations accepted at leading dermatology conferences



PHARMACFUTICALS

Fall Clinical Dermatology Conference, Oct 2025


Leading independent dermatology continuing medical education (CME) meeting attracting 1,200+ attendees




Society of Dermatology Physician Associates, Nov 2025

Leading CME event for dermatology PAs, combining clinical education, networking, and updates on new therapies

Two scientific posters accepted:



One scientific poster accepted:



Three key pillars will drive Botanix's near- and long-term value



Strong Opportunity for Lead Asset, Sofdra®



Differentiated Fulfilment Platform



Solid Foundation for Growth and Profitability

